Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX Plus Pemolivimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
NCT07651007Phase 2Not yet recruiting
- Start
- May 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of pucotenlimab in rectal cancer. Planned start May 2026; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07651007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07651007.